Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: A phase I-II study

Oncology

Volumn 64, Issue 2, 2003, Pages 139-145

  Barone, Carlo ^a   Cassano, A ^a   Corsi, D C ^a   Pozzo, C ^a   Longo, R ^a   Schinzari, G ^a   Quirino, M ^a   Battelli, C ^a   Basso, M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

5 Fluorouracil; Chemotherapy; Gemcitabine; Pancreatic cancer; Phase I

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; LIVER TOXICITY; MALE; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037256383     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067775     Document Type: Article

References (24)

1. Parker SL, Tong T, Bold S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Kelly DM, Benjamin IS: Pancreatic carcinoma. Ann Oncol 1995;6:19-28.
3. Schnall SF, MacDonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996;23:220-228.
4. Weh HJ, Wilke HJ, Dierlamm J, Klassen U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld U, Steinke B: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1994;5:233-237.
5. Kohne CH, Schoffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dorken B, Schmoll HJ: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-426.
6. Lutz MP, Koniger M, Muche R, Ellenrieder V, Steinkamp M, Adler G, Gress TM: A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer. Z Gastroenterol 1999;37:993-997.
7. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabineseq (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
8. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-105.
9. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps ML, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stefens CD, von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
10. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarasoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353.
11. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W: Inhibition of ribonucleotide reductase in CCRF-CEM cells by 2′2′-difluorodeoxycytidine. Mol Pharmacol 1990;38:567-572.
12. Division of Cancer Treatment, National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, National Cancer Institute, 1988.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
14. Andersen JS, Burris HA, Casper E: Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 1995;13:461.
15. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Cascinu S, Silva RR, Barni S, Labianca R, Frontini L, Piazza E, Pancera G, Giordani P, Giuliodori L, Pessi MA, Fusco V, Luporini G, Cellerino R, Catalano G: A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 1999;80:1595-1598.
17. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999;17:585-592.
18. Oettle H, Pelzer U, Hochmuth K, Diebold T, Langrehr J, Schmidt CA, Arning M, Vogl TS, Neuhaus P, Huhn D, Riess H: Phase I trial of gemcitabine (Gemzar), 24-h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. Anticancer Drugs 1999;10:699-704.
19. Oettle H, Arning M, Pelzer U, Arnold D, Stroszczynski C, Langrehr J, Reitzig P, Kindler M, Herrenberger J, Musch R, Korsten EW, Huhn D, Riess H: A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol 2000;11:1267-1272.
20. Berlin JD, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Harris JE, Benson AB III: A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group Study (E3296). Oncology 2000;58:215-218.
21. Louvet C, Andrè P, Hammel P, Selle F, Landi B, Cattan S, Fonck H, Flesch M, Colin P, Balasso J, Ruszniewski P, deGramont A: Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 2001;12:675-680.
22. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 1991;9:2128-2133.
23. Weinerman BH, MacCormick RE: A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population. Am J Clin Oncol 1994;17:467-469.
24. Ren Q, Kao V, Grem JL: Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 1998;4:2811-2818.